BRL 42852ER;LY 024410;9(s)-erythromycylamine;erythromyclamine, (9R)-isomer;(9S)-9-Amino-9-deoxoerythromycin

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: BRL 42852ER;LY 024410;9(s)-erythromycylamine;erythromyclamine, (9R)-isomer;(9S)-9-Amino-9-deoxoerythromycin
• 英文别名: 10-amino-6-[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one
• 化学式: C₃₇H₇₀N₂O₁₂
• 分子量: 735.0
• InChiKey: XCLJRCAJSCMIND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  51
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  203
• 氢给体数：
  6
• 氢受体数：
  14

文献信息

• Compounds, compositions and methods for treatment of inflammatory diseases and conditions
  申请人：PLIVA Pharmaceutical Industry, Incorporated

  公开号：US20040014685A1

  公开（公告）日：2004-01-22

  The present invention relates (a) to new compounds represented by Formula I: 1 wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, S represents a steroid subunit (steroid moiety) derived from steroid drug with anti-inflammatory activity and L represents a linker molecule linking M and S, (b) to their pharmacologically acceptable salts, prodrugs and solvates, (c) to processes and intermediates for their preparation, and (d) to their use in the treatment of inflammatory diseases and conditions in humans and animals. Such compounds inhibit many cytokines and immune mediators involved in immune responses which cause inflammation, allergy, or alloimmunity, including without limitation IL-1, 2, 4, 5, 6, 10, 12, GMCSF, ICAM, and TNF-&agr; Importantly, anti-inflammatory steroids exert a direct anti-inflammatory effect through binding to the glucocorticosteroid receptor.

  本发明涉及以下内容：(a) 由以下式I所表示的新化合物：其中M代表来源于具有在炎症细胞中积聚特性的大环内酯亚基（大环内酯基团），S代表来源于具有抗炎活性的类固醇药物的类固醇亚基（类固醇基团），L代表连接M和S的连接分子，(b) 它们的药理学可接受的盐、前药和溶剂化物，(c) 用于它们的制备的过程和中间体，以及(d) 用于治疗人类和动物的炎症性疾病和症状。这些化合物抑制许多参与导致炎症、过敏或移植免疫反应的细胞因子和免疫介质，包括但不限于IL-1、2、4、5、6、10、12、GMCSF、ICAM和TNF-α。重要的是，抗炎类固醇通过结合糖皮质类固醇受体直接发挥抗炎作用。
• C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes
  申请人：Combrink Keith

  公开号：US20050256096A1

  公开（公告）日：2005-11-17

  Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to C-25 carbamate derivatives of rifamycin having another functional group or pharmacophore covalently attached to this position through a carbamate linkage. The resulting compounds exert their antimicrobial activity through a dual-function mechanism and therefore exhibit reduced frequency of resistance.

  当前发明的化合物涉及具有抗微生物活性的利福霉素衍生物，包括针对耐药微生物的活性。更具体地说，当前发明的化合物涉及利福霉素的C-25氨基甲酸酯衍生物，通过氨基甲酸酯键连接到该位置的另一个功能基团或药效团。由此产生的化合物通过双重功能机制发挥其抗微生物活性，因此表现出较低的抗药性频率。
• Anti-Inflammatory Macrolide Conjugates
  申请人：Mercep Mladen

  公开号：US20080096830A1

  公开（公告）日：2008-04-24

  The present invention relates (a) to new compounds represented by Formula I: wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, D represents a dibenzo[e,h]azulene subunit with anti-inflammatory, analgesic and/or antipyretic activity and L represents a linking group covalently linking M and D; (b) to their pharmacologically acceptable salts, prodrugs and solvates, (c) to processes and intermediates for their preparation, and (d) to their use in the treatment of inflammatory diseases and conditions in humans and animals.

  本发明涉及(a)由式I所表示的新化合物，其中M代表源自具有在炎症细胞中积累特性的大环内酯亚基（大环内酯基团），D代表具有抗炎、镇痛和/或退热活性的二苯并[e，h]蓝亚基，L代表共价连接M和D的连接基；(b)它们的药理学可接受的盐、前药和溶剂化物，(c)制备它们的过程和中间体，以及(d)它们在治疗人类和动物的炎症性疾病和病况中的应用。
• Rifamycin derivatives effective against drug-resistant microbes
  申请人：Ma Zhenkun

  公开号：US20050261262A1

  公开（公告）日：2005-11-24

  Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.

  本发明涉及具有抗微生物活性的利福霉素衍生物，包括对耐药微生物的活性。本发明的利福霉素衍生物独特地设计在于，它们具有利福霉素基团通过利福霉素基团的C-3碳与连接基团共价连接，并且连接基团进一步与治疗性基团或抗菌剂/药效团共价连接。治疗性基团可以是喹诺酮、噁唑烷酮、大环内酯、氨基糖苷、四环素核心或与抗菌剂相关的结构/药效团。
• Fluorescent probes for ribosomes and method of use
  申请人：Ma Zhenkun

  公开号：US20050118624A1

  公开（公告）日：2005-06-02

  Fluorescent probes that have binding affinity to ribosomes. The fluorescent probes are useful tools for identifying small molecules that bind to the 50S or 30S subunits of the bacterial and other ribosomes and serve as novel ribosome inhibitors. These probes are also useful for determining the interactions between a specific ligand and the ribosome.

  具有与核糖体结合亲和力的荧光探针。这些荧光探针是用于识别与细菌和其他核糖体的50S或30S亚基结合的小分子，并作为新型核糖体抑制剂的有用工具。这些探针还有助于确定特定配体与核糖体之间的相互作用。